Contraindicated Use of Bevacizumab and Toxicity in Elderly Patients With Cancer [Health Services and Outcomes]
Conclusion
Our study demonstrates widespread use of bevacizumab among patients who had contraindications. Black patients were less likely to receive the drug, but those who did were more likely to have a contraindication. Efforts to understand toxicity and efficacy in populations excluded from clinical trials are needed.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Hershman, Wright, Lim, Buono, Tsai, Neugut Tags: Quality of Care, Quality of Care Health Services and Outcomes Source Type: research
More News: Avastin | Cancer | Cancer & Oncology | Clinical Trials | Colon Cancer | Colorectal Cancer | Databases & Libraries | Hemorrhagic Stroke | Medicare | Stroke | Study | Thrombosis | Toxicology